Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tocilizumab Safety Extension in RA
NCT01214733Phase 3Completed
- Sponsor
- Roche
- Start
- Oct 2010
- Primary completion
- May 2011
- Modality
- Antibody Conjugates, Recombinant Proteins and Enzymes, Engineered Antibody Formats
- Countries
- 1
01
Overview
A Phase 3 trial of tocilizumab in rheumatoid arthritis (RA), sponsored by Roche. Started Oct 2010; status: completed.
02
Drugs
tocilizumab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT01214733.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01214733.